Headache News and Research

Latest Headache News and Research

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received the industry's first and only regulatory approval for the use of an implanted neurostimulation device for patients with intractable chronic migraine.

7 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Many athletes hold unscientific views about benefits of different hydration practices

Nearly half of recreational runners may be drinking too much fluid during races, according to a survey of runners by Loyola University Health System researchers.

3 Sep 2011

AAN calls all high school coaches, athletes and parents to learn signs of sports concussion

The American Academy of Neurology, the leading group of neurologists dedicated to managing sports concussion, is issuing a call to all youth and high school coaches, athletes and parents to learn the signs of sports concussion and to know when a player must leave the game.

2 Sep 2011

New meta-analysis reaffirms safety profile of aspirin for pain relief, fever

A new meta-analysis published this week in Drugs in R&D, reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed.

2 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

Eisai announces results of perampanel Phase III study on epilepsy

Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and 12 mg, produced statistically significant reductions in median seizure frequency compared to placebo among patients having partial-onset seizures while receiving treatment with one to three other epilepsy drugs.

31 Aug 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX for injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

25 Aug 2011

Mylan subsidiary to exclusively offer EpiPen 2-Pak and EpiPen Jr 2-Pak Auto-Injector

Dey Pharma, L.P., a subsidiary of Mylan Inc., today announced that Dey will exclusively offer the EpiPen 2-Pak and EpiPen Jr 2-Pak (epinephrine) Auto-Injector 0.3/0.15 mg, to encourage physicians and patients to follow recommendations by the National Institute of Allergy and Infectious Diseases (NIAID).

24 Aug 2011

United Therapeutics completes treprostinil diethanolamine Phase 3 trial in PAH

United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.

24 Aug 2011

$New invasive procedures may help patients with chronic refractory headache$

New invasive procedures may help patients with chronic refractory headache

Cluster headache has a substantial detrimental effect on quality of life. New invasive procedures, such as hypothalamic deep brain stimulation and bilateral occipital nerve stimulation, may help patients with chronic refractory headache.

24 Aug 2011

NovaDel, Rechon enter license and distribution agreement for Zolpimist

NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

23 Aug 2011

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Traumatic brain injury has entered the public's consciousness as the silent, signature wound brought back by many of our military warriors from Iraq and Afghanistan. But such injuries don't only happen in warfare, they happen to civilians too. Think car crashes, a slip and fall, two football players colliding helmet to helmet.

22 Aug 2011

Female TBI patients more likely to report headaches during first year after injury

Recurring headaches are common during the year following a traumatic brain injury (TBI), regardless of the severity of the TBI, and they tend to occur more often among females and those with a pre-TBI history of headache, according to an article in Journal of Neurotrauma, a peer-reviewed journal published by Mary Ann Liebert, Inc.

19 Aug 2011

FDA approves two new strengths of Lupron Depot-PED for central precocious puberty

Abbott announced today that the U.S. Food and Drug Administration has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).

17 Aug 2011

Study finds sharp increase in CT scan use in ED between 1996-2007

A review of national data from 1996 through 2007 reveals a sharp uptick in the use of computed tomography, or CT, scans to diagnose illnesses in emergency departments, a University of Michigan Health System study finds.

11 Aug 2011

Caffeine can treat postdural puncture headaches

People who suffer headaches after a spinal tap might have a relatively simple way to ease the painful throb: a caffeine tablet.

11 Aug 2011

Headache News and Research

Latest Headache News and Research

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Many athletes hold unscientific views about benefits of different hydration practices

AAN calls all high school coaches, athletes and parents to learn signs of sports concussion

New meta-analysis reaffirms safety profile of aspirin for pain relief, fever

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

Eisai announces results of perampanel Phase III study on epilepsy

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Mylan subsidiary to exclusively offer EpiPen 2-Pak and EpiPen Jr 2-Pak Auto-Injector

United Therapeutics completes treprostinil diethanolamine Phase 3 trial in PAH

New invasive procedures may help patients with chronic refractory headache

NovaDel, Rechon enter license and distribution agreement for Zolpimist

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Female TBI patients more likely to report headaches during first year after injury

FDA approves two new strengths of Lupron Depot-PED for central precocious puberty

Study finds sharp increase in CT scan use in ED between 1996-2007

Caffeine can treat postdural puncture headaches

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in